Company Overview and News

 
Will Bond ETFs Sustain Their April Momentum in May?

2018-05-02 zacks
The fixed income world gained immense investors' love in April amid persistent stock market volatility. This is especially true as bond ETFs accumulated $14.7 billion last month, representing the highest monthly inflows since October 2014, according to data from BlackRock (read: ETF Asset Report for April 2018: Bonds Top). iShares Short Treasury Bond ETF (SHV - Free Report) topped the list of asset creation, pulling in more than $2.

 
My Current View Of The S&P 500 Index: May 2018 Edition

2018-05-01 seekingalpha
After two months of negative returns, the month of April was positive for my retirement account and all of the equity ETFs I follow. The market, as measured by the S&P 500 index, closed 0.27% higher in April. As for my pension plan assets, I had a positive return and my return beat the S&P 500 index in April. Consequently, I reached both of my investment objectives. My first investment objective, preservation of capital, was achieved with my positive return of 0.

 
ETF Asset Report for April 2018: Bonds Top

2018-04-30 zacks
The month of April was mixed with earnings showing promise and broader markets returning decent returns despite rising yields and trade tensions. Oil has been on an uptrend. Overall, SPDR S&P 500 ETF (SPY - Free Report) gained about 3.5% in a month’s time (as of Apr 27, 2018), SPDR Dow Jones Industrial Average ETF (DIA - Free Report) rose 2.9% while Nasdaq-100-bsed ETF PowerShares QQQ ETF (QQQ - Free Report) jumped 4.

 
ETFs In Focus: Top Ideas For The Week Of 4/2/2018

2018-04-02 seekingalpha
Each week, I scan the ETF marketplace to identify the top ETF ideas that present opportunities you should be aware of for the upcoming week.

 
My Current View Of The S&P 500 Index: April 2018

2018-03-30 seekingalpha
The month of March was another tough one for equity investors. Two of the indices that I monitor declined in March, but one of the equity indices I monitor did move higher. The market, as measured by the S&P 500 index, closed 2.69% lower in March making back to back down months for the first time in quite some time. The SPDR S&P 500 ETF (SPY) lost 2.74% for the month. As for my pension plan assets, I lost money in March.

 
5 Best iShares ETFs: A Core Portfolio For Fidelity Brokerage Clients - Part 2

2018-03-23 seekingalpha
Whether you are already a Fidelity Brokerage client, or just starting your journey in the world of investing, this two-part article is for you.

 
U.S. Fund-Flows Weekly Report: Funds Experience Overall Net Inflows, Driven By Money Market Funds

2018-03-10 seekingalpha
Thomson Reuters Lipper's fund asset groups (including both mutual funds and ETFs) took in net new money of $2.4 billion for the fund-flows week ended Wednesday, March 7. The net inflows were driven by money market funds (+$12.7 billion) and municipal bond funds (+$407 million), while equity funds (-$9.8 billion) and taxable bond funds (-$898 million) saw money leave.

 
My Current View Of The S&P 500 Index - March 2018

2018-03-01 seekingalpha
The long sought after correction finally came, or it at least began. All of the indices that I monitor corrected in February. It is fair to say that those indices rebounded from their lows during the month as well, but they all closed lower for the month. The market, as measured by the S&P 500 index, closed 3.89% lower in February. The SPDR S&P 500 ETF (SPY) lost 3.64% for the month. As for my pension plan assets, I lost money in February.

 
Paul Tudor Jones Prefers A Hot Burning Coal Over Treasuries

2018-02-20 seekingalpha
According to CNBC Hedge fund billionaire Paul Tudor Jones says we are in a dangerous financial bubble thanks to Fed policy. Especially the 2 percent inflation target is a goal that is outdated and dangerous according to the Hedge Funder.

 
Aggregate Bond ETF (AGG) Hits a New 52-Week Low

2018-02-08 zacks
Investors looking to avoid underperformance should steer clear of iShares Core U.S. Aggregate Bond ETF (AGG - Free Report) . The fund recently hit a new 52-week low. Shares of AGG are down roughly 3.2% from its 52-week high of $110.66/share.

 
U.S. Weekly FundFlows Insight Report: Long-Term Assets Attract Inflows For The Week

2018-02-02 seekingalpha
For the second week in three, investors were net sellers of fund assets (including those of conventional funds and ETFs), withdrawing $6.0 billion. However, the headline number once again was a little misleading. Fund investors were net redeemers of money market funds, withdrawing $26.0 billion, but they were net purchasers of long-term assets, padding the coffers of equity funds (+$16.2 billion), taxable bond funds (+$3.

 
My Current View Of The S&P 500 Index - February 2018

2018-02-01 seekingalpha
The stock market started the year by posting a strong gain. The market, as measured by the S&P 500 index, closed 5.62% higher in January. The SPDR S&P 500 ETF (SPY) gained 5.64% for the month. As for my pension plan assets, I made money in January. Consequently, my first investment goal, preservation of capital, was achieved. Unfortunately, I did not beat the returns of the S&P 500 index as measured by SPY.

 
AGG / iShares Core U.S. Aggregate Bond ETF - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-23 fintel.io
iShares Core U.S. Aggregate Bond ETF (NYSE:AGG) has 754 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 354,366,924 shares. Largest shareholders include Jones Financial Companies Lllp, BlackRock Inc., Wells Fargo & Company/mn, Bank Of America Corp /de/, Raymond James & Associates, Amerivest Investment Management LLC, Creative Planning, Milliman Financial Risk Management LLC, Envestnet Asset Management Inc, and JP Morgan Chase & Co.

 
AGG / iShares Core U.S. Aggregate Bond ETF / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-23 sec.gov
us4642872265_012318.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ISHARES CORE U.S. AGGREGATE BOND ETF -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 464287226 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ---------------------------------

 
AGG / iShares Core U.S. Aggregate Bond ETF / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-23 sec.gov
us4642872265_012318.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ISHARES CORE U.S. AGGREGATE BOND ETF -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 464287226 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ---------------------------------

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 464287226